We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
VBI Vaccines (VBIV) is in Overbought Territory: What's Next?
Read MoreHide Full Article
VBI Vaccines Inc. (VBIV - Free Report) has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because VBIV is now in overbought territory with an RSI value of 71.79.
What is RSI?
RSI stands for ‘Relative Strength Index’ and it is a popular indicator used by technically focused investors. It compares the average of gains in days that closed up to the average of losses in days that closed down; readings above 70 suggest an asset is overbought, while an RSI below 30 suggests undervalued conditions are present.
Other Factors
Yet VBIV’s high RSI value isn’t the only reason for investors to be concerned, as there has been some decidedly negative earnings estimate revisions VBI Vaccines’ stock as of late. This is especially true when investors dive into some of these revisions in order to get a better picture of VBIV’s prospects for the near term.
Over the past one month, investors have witnessed 1 earnings estimate revision lower compared to none higher for the current year. The consensus estimate for VBIV’s has also been on a downward trend over the same time period too, as the estimates have fallen 11.1% over the last two months.
If this wasn’t enough, VBI Vaccines also has a Zacks Rank #4 (Sell) which puts it into unfortunate company among its peers. So, given all of these factors, investors may want to consider exiting this stock now before it falls back to Earth. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
+1,500% Growth: One of 2021’s Most Exciting Investment Opportunities
In addition to the stocks you read about above, would you like to see Zacks’ top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.
Zacks has released a special report to help you capitalize on the Internet of Things’s exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond.
Image: Bigstock
VBI Vaccines (VBIV) is in Overbought Territory: What's Next?
VBI Vaccines Inc. (VBIV - Free Report) has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because VBIV is now in overbought territory with an RSI value of 71.79.
What is RSI?
RSI stands for ‘Relative Strength Index’ and it is a popular indicator used by technically focused investors. It compares the average of gains in days that closed up to the average of losses in days that closed down; readings above 70 suggest an asset is overbought, while an RSI below 30 suggests undervalued conditions are present.
Other Factors
Yet VBIV’s high RSI value isn’t the only reason for investors to be concerned, as there has been some decidedly negative earnings estimate revisions VBI Vaccines’ stock as of late. This is especially true when investors dive into some of these revisions in order to get a better picture of VBIV’s prospects for the near term.
Over the past one month, investors have witnessed 1 earnings estimate revision lower compared to none higher for the current year. The consensus estimate for VBIV’s has also been on a downward trend over the same time period too, as the estimates have fallen 11.1% over the last two months.
If this wasn’t enough, VBI Vaccines also has a Zacks Rank #4 (Sell) which puts it into unfortunate company among its peers. So, given all of these factors, investors may want to consider exiting this stock now before it falls back to Earth. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
+1,500% Growth: One of 2021’s Most Exciting Investment Opportunities
In addition to the stocks you read about above, would you like to see Zacks’ top picks to capitalize on the Internet of Things (IoT)? It is one of the fastest-growing technologies in history, with an estimated 77 billion devices to be connected by 2025. That works out to 127 new devices per second.
Zacks has released a special report to help you capitalize on the Internet of Things’s exponential growth. It reveals 4 under-the-radar stocks that could be some of the most profitable holdings in your portfolio in 2021 and beyond.
Click here to download this report FREE >>